Physician profile
John Henry Baker
NPI 1245299106
$2,876.48
in general payments reported to CMS, 2019-2025
12 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $162 · 2021: $271 · 2022: $191 · 2023: $454 · 2024: $886 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,089.88 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $264.04 | 2022-2024 | Dupixent |
| Genzyme Corporation | $174.27 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $96.85 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.22 | 2023 | Cyltezo |
| Alfasigma USA, INC. | $45.74 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $43.14 | 2021-2022 | |
| Amgen INC. | $41.11 | 2022-2023 | Amjevita, Avsola |
| Ironwood Pharmaceuticals, INC | $21.55 | 2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $20.45 | 2021 | |
| Shire North American Group INC | $19.23 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,290.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.